VIVO 16.91 Meridian Bioscience Inc $VIVO Hit a 52 week low

New Post Public Reply Private Reply Replies (0) Message Board
Emylers
VIVO 16.91 Meridian Bioscience Inc $VIVO Hit a 52 week low of 16.53 Closing the day 10:45 at 16.91 +0.03 +0.18% With a day low of 16.53 and a total volume of 119,862.

VIVO Recent Posts: http://investorshangout.com/Meridian-Bioscien...IVO-55809/

VIVO Meridian Bioscience Inc Recent Headline News

Healthcare's Top Dividend Paying Stocks
Sean Williams, The Motley Fool - Motley Fool - Thu Nov 13, 6:43AM CST
Source: Flickr user TaxRebate.org.uk. Dividends are the foundation to which all great long-term portfolio are built. Receiving a payment equal to 2% or 3% per year might not seem like much, but reinvested into that same growing company over the...
VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), GSK: 45.83 (+0.21), SNY: 46.66 (+0.10), PDLI: 7.93 (-0.09)

Meridian Bioscience (VIVO) Misses Q4 Earnings, Revenues - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 12, 9:20AM CST
Meridian Bioscience Inc. (VIVO) reported fourth-quarter fiscal 2014 earnings of 20 cents per share, which missed the Zacks Consensus Estimate by a couple of cents
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), OSUR: 9.18 (unch)

Meridian Bioscience Down 13.7% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Mon Nov 10, 9:45AM CST
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 3 months, Meridian Bioscience has returned 13.75% as of today's recent price of $16.91.
VIVO: 16.78 (-0.10)

Meridian Bioscience (VIVO) Falls: Stock Goes Down 5.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 10, 7:55AM CST
Meridian Bioscience saw a big move last session, as the company’s shares fell by nearly 6% which continued the recent downtrend
VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91), GWPH: 75.29 (-0.03), OSUR: 9.18 (unch)

Downgrade Alert for Meridian Bioscience (VIVO)
Comtex SmarTrend(R) - Fri Nov 07, 6:59AM CST
Meridian Bioscience (NASDAQ:VIVO) was downgraded from Outperform to Neutral at RW Baird today. The stock closed yesterday at $17.91 on volume of 374,000 shares, above average daily volume of 203,000. Over the past year, Meridian Bioscience has traded in a range of $17.12 to $27.72 and closed yesterday at $17.91, 5% above that low. The 200-day and 50-day moving averages have moved 0.73% lower and 0.51% lower over the past week, respectively.
VIVO: 16.78 (-0.10)

Meridian Bioscience misses Street 4Q forecasts
Automated Insights - Thu Nov 06, 10:18AM CST
CINCINNATI (AP) _ Meridian Bioscience Inc. (VIVO) on Thursday reported fiscal fourth-quarter net income of $8.2 million.
VIVO: 16.78 (-0.10)

Meridian Bioscience declares $0.20 dividend
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:55AM CST

VIVO: 16.78 (-0.10)

Meridian Bioscience misses by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 7:02AM CST

VIVO: 16.78 (-0.10)

Meridian Bioscience Reports Fourth Quarter and Full-Year Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2015 Guidance
Business Wire - Thu Nov 06, 6:30AM CST
Meridian Bioscience, Inc. (NASDAQ: VIVO):
VIVO: 16.78 (-0.10)

7 Old Dividend Dogs Of Healthcare Aim At 11% To 30.5% October Upsides
Fredrik Arnold - at Seeking Alpha - Mon Nov 03, 11:21AM CST

KND: 20.42 (-0.36), VIVO: 16.78 (-0.10), PETS: 13.60 (-0.08), PFE: 30.52 (+0.10), GSK: 45.84 (+0.22), MR: 31.46 (-0.03), SEM: 13.63 (-0.01), PDLI: 7.93 (-0.09), SNN: 33.58 (+0.05), AZN: 74.57 (+0.31), MRK: 59.67 (+0.36), STJ: 65.86 (+0.18), TRIB: 17.81 (-0.40), ABBV: 64.00 (+0.24), THRX: 13.36 (+0.04), SNY: 46.66 (+0.10)

Meridian Bioscience Down 9.6% Since SmarTrend Downtrend Call (VIVO)
Comtex SmarTrend(R) - Thu Oct 23, 9:58AM CDT
SmarTrend identified a Downtrend for Meridian Bioscience (NASDAQ:VIVO) on August 27th, 2014 at $19.61. In approximately 2 months, Meridian Bioscience has returned 9.61% as of today's recent price of $17.72.
VIVO: 16.78 (-0.10)

Meridian Bioscience Offers Testing Solutions to Premier - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 04, 12:50PM CDT
The illumigene molecular system uses loop-mediated isothermal DNA amplification technology, which is an efficient system to allow Meridian Bioscience (VIVO) to provide customers the illumipro 10 instrument without a capital investment or costly annual service contract.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)

Meridian Bioscience's Earnings Outlook Show Flat Growth - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 12:40PM CDT
Meridian Bioscience (VIVO) also expects net revenues to grow in the range of 2 to 5% to approximately between $193 and $200 million for fiscal 2015.
ICUI: 84.30 (-0.43), SMA: 9.45 (-0.03), VIVO: 16.78 (-0.10), ABAX: 55.11 (+0.91)

Meridian Bioscience Signs Agreement with Premier, Inc. to Offer Its Hospitals Molecular Diagnostic Tests and Instruments for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae
Business Wire - Wed Sep 03, 6:30AM CDT
Meridian Bioscience Inc., Cincinnati, Ohio (NASDAQ:VIVO) today announced it has signed a new agreement with Premier, Inc. to offer the complete illumigene(R) molecular menu of tests to its members. Premier serves more than 3,000 U.S. hospitals and 110,000-plus other healthcare sites. This agreement offers each Premier healthcare facility the opportunity to implement rapid, sensitive, molecular tests for C. difficile, Group B Streptococcus, Group A Streptococcus, Bordetella pertussis, and Mycoplasma pneumoniae on the illumigene molecular platform without individual negotiations.
VIVO: 16.78 (-0.10), PINC: 31.44 (-0.08)

Meridian Bioscience Provides Net Revenues and Earnings Guidance for Fiscal 2015 and Reaffirms Fiscal 2014 Guidance
Business Wire - Tue Sep 02, 6:30AM CDT
Meridian Bioscience, Inc., Cincinnati, Ohio (NASDAQ: VIVO) today provided the financial community with guidance regarding the Company's fiscal 2015 sales and earnings estimates. Based on the Company's business planning and budgeting activities for the fiscal year ending September 30, 2015, management expects net revenues to be in the range of $193 to $200 million, or 2% to 5% growth, and per share diluted earnings to be between $0.85 and $0.91. The per share estimates assume an increase in average diluted shares outstanding from approximately 42.2 million at fiscal 2014 year end to 42.4 million at fiscal 2015 year end. The revenues and earnings guidance provided in this press release is from expected internal growth and does not include the impact of any acquisitions the Company might complete during fiscal 2015.
VIVO: 16.78 (-0.10)

3 Value Stocks to Consider for Your Portfolio
Sean Williams, The Motley Fool - Motley Fool - Tue Aug 26, 12:32PM CDT
Just as we often examine companies that may be rising past their fair values, we can also find companies trading at what may be bargain prices. While many investors would rather have nothing to do with stocks wallowing at 52-week lows, I think it...
VIVO: 16.78 (-0.10), RIG: 26.26 (-0.82), BAGL: 20.23 (-0.01)

Meridian Bioscience partners with University of Tennessee Research Foundation to develop electrokinetic sensor technology
M2 - Thu Aug 07, 6:58AM CDT
Life science company Meridian Bioscience (NasdaqGS:VIVO) announced on Wednesday that it executed a technology and commercial license agreement for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)

Meridian Bioscience and the University of Tennessee Research Foundation Enter into a License Agreement for Electrokinetic Sensor Technology
Business Wire - Wed Aug 06, 8:00AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO), today announced that it has entered into a technology and commercial license agreement with the University of Tennessee Research Foundation (UTRF) for the development of an innovative new technology that has the potential to result in a low cost, point-of-care detection platform capable of detecting proteins, small molecules, bacteria and viruses in minutes.
VIVO: 16.78 (-0.10)

Meridian Bioscience Q3 Earnings, Revenues Miss Estimates - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Jul 28, 12:58PM CDT
For fiscal 2014, Meridian Bioscience, Inc. (VIVO) expects earnings per share between 85 and 90 cents while revenues are expected in the range of $190 to $195 million.
BSX: 13.36 (-0.05), VIVO: 16.78 (-0.10), ALR: 39.91 (-0.19), OSUR: 9.18 (unch)

Meridian Bioscience Reports Third Quarter and Nine Months Operating Results, Declares Regular Cash Dividend, and Reaffirms Fiscal 2014 Guidance
Business Wire - Thu Jul 24, 7:15AM CDT
Meridian Bioscience, Inc. (NASDAQ: VIVO) today:
VIVO: 16.78 (-0.10)
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Jumia’s Breakeven Retreat Invites Legal Scrutiny

Updated Category News Views 25

Jumia’s credibility problem did not arrive wearing a disguise. The company spent much of 2026 telling investors that a fourth-quarter Adjusted EBITDA breakeven was still on the table, then discarded that target after reporting third-quarter results. For holders of NYSE:JMIA, that kind of reversal stings because the promise was not some stray talking point; it was...

Continue Reading
Ambition Links Call Scoring to the Coaching Room Faster

Updated Category News Views 81

A sales call dies twice when nobody turns the recording into practice. First it ends with the prospect, then it vanishes into a pile of transcripts, dashboards, and manager good intentions. Ambition’s new Call Intelligence feature is aimed squarely at that second failure. It brings Gong calls, transcripts, scorecards, and trackers into Ambition’s coaching workflow,...

Continue Reading
Trinity's Minneapolis Move Signals Freight Momentum

Updated Category News Views 120

A suite change inside downtown Minneapolis is usually wallpaper, but this one carries a little more weight. Trinity Logistics has moved its Minneapolis team from Suite 1850 to Suite 1700 at 100 S. 5th Street, saying the larger space is needed for continued growth and future opportunity. Nobody should confuse an office relocation with a freight-cycle victory lap. Still,...

Continue Reading
Litmus Gets $475 Million as Music Rights Mature Further

Updated Category News Views 107

Music royalties just got another serious pile of institutional money, and Litmus is holding the shovel. The company announced roughly $475 million of new capital commitments from Carlyle and investment funds managed by KKR, a notable vote of confidence in a platform that did not even exist before 2022. This is not some celebrity vanity vehicle buying a famous chorus and...

Continue Reading
Mining's Biodiversity Map Sharpens Location Risks

Updated Category News Views 106

Twelve thousand pins on a map do not settle the mining industry's nature problem, but they do make it much harder to pretend the problem is evenly spread. ICMM's new Global Mining and Metals Biodiversity Dataset overlays 12,000 large-scale formal mining, smelting, refining and processing facilities with ecosystem-condition and conservation indicators. For investors...

Continue Reading
U.S. Patriot's Veteran Hiring Earns a Real National Nod

Updated Category News Views 43

A workforce award can be cheap wallpaper, but this one has some heft. U.S. Patriot, the veteran-founded and veteran-led military goods retailer owned by GALLS, landed on Military Times’ 2026 Best for Vets: Employers list, placing third in retail and first in Kentucky. The recognition covers 250 organizations, and this is U.S. Patriot’s fourth consecutive appearance....

Continue Reading
AMP Tests Debt Market With €1.25 Billion Green Notes

Updated Category News Views 167

Refinancing season has arrived early at Ardagh Metal Packaging, and it is carrying a hefty €1.25 billion price tag. AMP has launched senior secured floating-rate green notes, with proceeds intended to retire two batches of secured debt due in 2028 and leave additional cash on the balance sheet for general corporate purposes, including capital expenditure. This is not...

Continue Reading
Esquire Spotlight Puts Trauma Cleanup Work in Focus

Updated Category News Views 52

A national magazine profile is an odd milestone for a business built around other people’s worst days. David Lesaffre, co-owner and operator of T.A.C.T. 48, T.A.C.T. AZ, and T.A.C.T. Fort Worth, has been featured by Esquire in a piece called “The Trauma Cleaners.” The attention is deserved, frankly, because biohazard remediation is one of those necessary services...

Continue Reading
Star Catcher Powers a Public-Interest Space Bet Ahead

Updated Category News Views 56

A satellite’s battery budget is a rotten place for humanitarian priorities to die. Common Space and Star Catcher are trying to remove that bottleneck through a partnership that is easy to like on principle and still deserves a clear-eyed look on execution. Common Space, a nonprofit developing an independent, community-governed high-resolution satellite constellation,...

Continue Reading
Four Pending Deals Put Shareholder Terms Under Scrutiny

Updated Category News Views 101

Four corporate transactions landed under a legal microscope on November 18, and that is never background noise for shareholders trying to judge whether the paperwork matches the price. Halper Sadeh LLC says it is investigating proposed deals involving WaFd, Personalis, Dana and Baldwin Group for possible federal securities-law violations and/or fiduciary-duty breaches....

Continue Reading

Top 5 Most Recently Viewed Articles

Revolutionizing Customer Care: Apivia and SoundHound Unite

Updated Category News Views 247

Transforming Customer Service with AI SoundHound AI (NASDAQ: SOUN) has joined forces with Apivia Courtage, a notable entity within France's AEMA Group, which is recognized as a leading mutual insurance organization. This partnership aims to implement agent-based artificial intelligence into Apivia Courtage's customer service systems through the innovative Amelia 7...

Continue Reading
Taiwan's Bold Pedal Into Sustainability: EUROBIKE 2026

Updated Category News Views 40

Stepping Up the Game at EUROBIKE 2026 Ask any veteran cyclist: The road to innovation is a winding one, and Taiwan's Bicycle Industry seems determined to tackle every curve head-on at EUROBIKE 2026. This isn't just about flashy tech; it's a full-blown commitment to smart, low-carbon mobility—a real 'get on the bike or get left behind' moment. Unveiling the AI-Powered...

Continue Reading
TDI Welcomes Jay Truesdale as New Chief Executive Officer

Updated Category News Views 389

TD International Appoints New Leadership TD International LLC (TDI), a prominent strategic advisory and risk intelligence firm, has announced significant leadership changes with the appointment of Jay Truesdale as Chief Executive Officer. This move marks a pivotal moment for TDI, as it looks to leverage Truesdale's considerable expertise in geopolitics and global markets....

Continue Reading
Canaan Inc. Streamlines Focus on Core Cryptocurrency Market

Updated Category News Views 258

Canaan Inc. Streamlines Focus on Core Cryptocurrency Market Canaan Inc. (NASDAQ: CAN) has recently taken a significant step in refining its business operations. The company is discontinuing its non-core AI semiconductor division to concentrate on its core strengths in the ever-evolving world of cryptocurrency. This strategic decision is aimed at enhancing efficiencies and...

Continue Reading
Ascentage Pharma's Impressive Growth in 2025: A Review

Updated Category News Views 567

Overview of Ascentage Pharma's Interim Results Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855) recently announced its interim unaudited financial results for the first half of 2025. The report highlights significant growth, particularly in product sales, and provides exciting updates on ongoing clinical programs and commercial strategies. The company's...

Continue Reading